L
Lukas Bunse
Researcher at German Cancer Research Center
Publications - 52
Citations - 3275
Lukas Bunse is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 14, co-authored 37 publications receiving 2064 citations. Previous affiliations of Lukas Bunse include Brigham and Women's Hospital & Heidelberg University.
Papers
More filters
Journal ArticleDOI
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor
Veit Rothhammer,Ivan D. Mascanfroni,Lukas Bunse,Maisa C. Takenaka,Jessica E. Kenison,Lior Mayo,Chun-Cheih Chao,Bonny Patel,Raymond Yan,Manon Blain,Jorge I. Alvarez,Hania Kebir,Niroshana Anandasabapathy,Guillermo Izquierdo,Steffen Jung,Nikolaus D. Obholzer,Nikolaus D. Obholzer,Nathalie Pochet,Nathalie Pochet,Clary B. Clish,Marco Prinz,Alexandre Prat,Jack P. Antel,Francisco J. Quintana +23 more
TL;DR: Findings suggest that IFN-Is produced in the CNS function in combination with metabolites derived from dietary tryptophan by the gut flora to activate AHR signaling in astrocytes and suppress CNS inflammation.
Journal ArticleDOI
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher,Lukas Bunse,Stefan Pusch,Felix Sahm,Benedikt Wiestler,Jasmin Quandt,Oliver Menn,Matthias Osswald,Iris Oezen,Martina Ott,Melanie Keil,Jörg Balß,Katharina J. Rauschenbach,Agnieszka K. Grabowska,Isabel Vogler,Jan Diekmann,Nico Trautwein,Stefan B. Eichmüller,Jürgen G. Okun,Stefan Stevanovic,Angelika B. Riemer,Ugur Sahin,Manuel A. Friese,Philipp Beckhove,Andreas von Deimling,Wolfgang Wick,Michael Platten +26 more
TL;DR: It is demonstrated that IDH1(R132H) contains an immunogenic epitope suitable for mutation-specific vaccination and Peptides encompassing the mutated region are presented on major histocompatibility complexes (MHC) class II and induce mutation- specific CD4+ T-helper-1 (TH1) responses.
Journal ArticleDOI
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf,Sabrina Kuttruff-Coqui,Katrin Frenzel,Valesca Bukur,Stefan Stevanovic,Stefan Stevanovic,Cécile Gouttefangeas,Cécile Gouttefangeas,Michael Platten,Michael Platten,Ghazaleh Tabatabai,Ghazaleh Tabatabai,Valérie Dutoit,Sjoerd H. van der Burg,Per thor Straten,Per thor Straten,Francisco Martínez-Ricarte,Berta Ponsati,Hideho Okada,Ulrik Lassen,Arie Admon,Christian H. Ottensmeier,Alexander Ulges,Sebastian Kreiter,Andreas von Deimling,Andreas von Deimling,Marco Skardelly,Denis Migliorini,Judith R. Kroep,Manja Idorn,Manja Idorn,Jordi Rodon,Jordi Rodon,Jordi Piro,Hans Skovgaard Poulsen,Bracha Shraibman,Katy J. McCann,Regina Mendrzyk,Martin Löwer,Monika Stieglbauer,Cedrik M. Britten,David Capper,David Capper,David Capper,Marij J. P. Welters,Juan Sahuquillo,Katharina Kiesel,Evelyna Derhovanessian,Elisa Rusch,Lukas Bunse,Lukas Bunse,Colette Song,Sandra Heesch,Claudia Wagner,Alexandra Kemmer-Brück,Jorg Ludwig,John C. Castle,Oliver Schoor,Arbel D. Tadmor,Edward W. Green,Jens Fritsche,Miriam Meyer,Nina Pawlowski,Sonja Dorner,Franziska Hoffgaard,Bernhard Rossler,Dominik Maurer,Toni Weinschenk,Carsten Reinhardt,Christoph Huber,Hans-Georg Rammensee,Hans-Georg Rammensee,Harpreet Singh-Jasuja,Ugur Sahin,Pierre-Yves Dietrich,Wolfgang Wick,Wolfgang Wick +76 more
TL;DR: In a phase I trial, highly individualized peptide vaccines against unmutated tumour antigens and neoepitopes elicited sustained responses in CD8+ and CD4+ T cells, respectively, in patients with newly diagnosed glioblastoma.
Journal ArticleDOI
Suppression of antitumor T cell immunity by the oncometabolite ( R )-2-hydroxyglutarate
Lukas Bunse,Stefan Pusch,Theresa Bunse,Felix Sahm,Khwab Sanghvi,Khwab Sanghvi,Mirco Friedrich,Dalia Alansary,Jana K. Sonner,Edward W. Green,Katrin Deumelandt,Katrin Deumelandt,Michael Kilian,Michael Kilian,Cyril Neftel,Stefanie Uhlig,Tobias Kessler,Anna von Landenberg,Anna S. Berghoff,Kelly Marsh,Mya Steadman,Dongwei Zhu,Brandon Nicolay,Benedikt Wiestler,Michael O. Breckwoldt,Michael O. Breckwoldt,Ruslan Al-Ali,Simone Karcher-Bausch,Matthias Bozza,Iris Oezen,Magdalena Kramer,Jochen Meyer,Antje Habel,Jessica Eisel,Gernot Poschet,Michael Weller,Matthias Preusser,Minou Nadji-Ohl,Niklas Thon,Michael C. Burger,Patrick N. Harter,Miriam Ratliff,Richard Harbottle,Axel Benner,Daniel Schrimpf,Jürgen G. Okun,Christel Herold-Mende,Sevin Turcan,Stefan Kaulfuss,Holger Hess-Stumpp,Karen Bieback,Daniel P. Cahill,Karl H. Plate,Daniel Hänggi,Marion Dorsch,Mario L. Suvà,Barbara A. Niemeyer,Andreas von Deimling,Wolfgang Wick,Michael Platten +59 more
TL;DR: An oncometabolite produced by tumor cells acts as a paracrine immunosuppressant dampening antitumor T cell responses in glioma, attribute a novel, non-tumor cell-autonomous role to an oncomETabolite in shaping the tumor immune microenvironment.
Journal ArticleDOI
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Michael Platten,Michael Platten,Lukas Bunse,Lukas Bunse,Antje Wick,Theresa Bunse,Theresa Bunse,Lucian Le Cornet,Inga Harting,Felix Sahm,Khwab Sanghvi,Chin Leng Tan,Isabel Poschke,Edward W. Green,Sune Justesen,Geoffrey A. Behrens,Michael O. Breckwoldt,Angelika Freitag,Lisa-Marie Rother,Anita Schmitt,Oliver Schnell,Jörg Hense,Martin Misch,Dietmar Krex,Stefan Stevanovic,Ghazaleh Tabatabai,Joachim P. Steinbach,Martin Bendszus,Andreas von Deimling,Michael Schmitt,Wolfgang Wick +30 more
TL;DR: In this paper, an IDH1(R132H)-specific peptide vaccine (IDH1-vac) was used to induce specific therapeutic T helper cell responses that are effective against the most common IDH 1 mutation in diffuse gliomas, which harbours a shared clonal neoepitope.